Arndt Schottelius has been appointed as chief executive officer of Maxion Therapeutics Ltd, effective 1 March, in a planned succession process, where co-founder John McCafferty is transitioning from CEO to chief technology officer. Maxion is developing antibody-based drugs for ion channel and GPCR-driven diseases. Dr Schottelius is joining the company from Affimed NV where he was chief scientific officer. He has also held executive leadership positions at Kymab (acquired by Sanofi) and MorphoSys AG, soon to be acquired by Novartis. Dr Schottelius holds an MD and PhD in medicine from the University of Freiburg and a habilitation in experimental medicine degree from Ludwig-Maximilian University Munich, both in Germany.
Maxion Therapeutics announced the appointment on 1 February 2024.
Copyright 2024 Evernow Publishing Ltd